Skip to main content

Table 5 Adverse events classified as nervous system disorders or psychiatric disorders reported across the entire tafenoquine development programme classified by total tafenoquine dose [74]

From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

Adverse event, n (%)

All placeboa (N = 794)

Total TQ 300 mg ≤ 3 days (N = 807)

Total TQ > 300 mg ≤ 3 days (N = 1482)

Total TQ > 300 mg > 3 days (N = 1445)

All TQb (N = 4129)

Any nervous system disorder

170 (21)

142 (18)

240 (16)

269 (19)

734 (18)

 Headache

149 (19)

98 (12)

164 (11)

211 (15)

544 (13)

 Migraine

4 (< 1)

3 (< 1)

0

3 (< 1)

8 (< 1)

 Sinus headache

1 (< 1)

0

0

4 (< 1)

4 (< 1)

 Tension headache

0

0

0

2 (< 1)

2 (< 1)

 Head discomfort

0

0

1 (< 1)

0

1 (< 1)

 Visual field defect

0

0

0

1 (< 1)

1 (< 1)

 Lethargy

0

0

28 (2)

28 (2)

56 (1)

 Somnolence

1 (< 1)

3 (< 1)

21 (1)

1 (< 1)

25 (< 1)

 Amnesia

0

0

0

1 (< 1)

1 (< 1)

 Depressed level of consciousness

0

1 (< 1)

0

0

1 (< 1)

 Disturbance in attention

0

0

1 (< 1)

0

1 (< 1)

 Dysgeusia

1 (< 1)

0

17 (1)

1 (< 1)

18 (< 1)

 Paraesthesia

0

0

3 (< 1)

4 (< 1)

8 (< 1)

 Hypoaesthesia

1 (< 1)

0

3 (< 1)

1 (< 1)

4 (< 1)

 Hyperaesthesia

0

0

0

1 (< 1)

2 (< 1)

 Burning sensation

0

0

0

0

1 (< 1)

 Coordination abnormal

0

0

0

2 (< 1)

2 (< 1)

 Balance disorder

0

1 (< 1)

0

0

1 (< 1)

 Dizziness

24 (3)

62 (8)

56 (4)

33 (2)

171 (4)

 Syncope

0

2 (< 1)

1 (< 1)

2 (< 1)

5 (< 1)

 Presyncope

0

0

0

1 (< 1)

1 (< 1)

 Dizziness postural

1 (< 1)

0

0

0

0

 Loss of consciousness

1 (< 1)

0

0

0

0

 Tremor

0

1 (< 1)

1 (< 1)

2 (< 1)

4 (< 1)

 Muscle contractions involuntary

0

0

1 (< 1)

0

1 (< 1)

 Sciatica

0

0

0

2 (< 1)

3 (< 1)

 Post herpetic neuralgia

0

0

1 (< 1)

1 (< 1)

2 (< 1)

 Trigeminal neuralgia

0

0

0

1 (< 1)

1 (< 1)

Any psychiatric disorder

8 (1)

16 (2)

19 (1)

37 (3)

79 (2)

 Insomnia

8 (1)

15 (2)

12 (< 1)

15 (1)

48 (1)

 Abnormal dreams

0

1 (< 1)

0

6 (< 1)

7 (< 1)

 Sleep disorder

0

0

0

3 (< 1)

3 (< 1)

 Nightmare

0

0

0

2 (< 1)

2 (< 1)

 Agitation

0

0

0

2 (< 1)

2 (< 1)

 Anxiety

0

2 (< 1)

0

0

2 (< 1)

 Anxiety disorder

0

0

0

2 (< 1)

2 (< 1)

 Irritability

0

0

1 (< 1)

0

2 (< 1)

 Neurosis

0

0

0

1 (< 1)

1 (< 1)

 Panic attack

0

0

0

1 (< 1)

1 (< 1)

 Psychotic disorder

0

0

1 (< 1)

0

1 (< 1)

 Stress

0

0

0

1 (< 1)

1 (< 1)

 Euphoric mood

0

0

1 (< 1)

2 (< 1)

3 (< 1)

 Depressed mood

0

0

1 (< 1)

1 (< 1)

2 (< 1)

 Depression

0

0

0

2 (< 1)

2 (< 1)

 Bipolar disorder

0

0

0

1 (< 1)

1 (< 1)

 Disinhibition

0

0

1 (< 1)

0

1 (< 1)

 Mood altered

0

0

1 (< 1)

0

1 (< 1)

 Alcoholic hangover

0

0

0

1 (< 1)

1 (< 1)

 Tic

0

0

1 (< 1)

0

1 (< 1)

  1. aThe placebo group includes healthy volunteers treated with placebo and P. vivax subjects treated with chloroquine alone in P. vivax relapse prevention
  2. bAlso includes 392 subjects who received < 300 mg total dose and 3 subjects who received 300 mg total dose > 3 days